Blood Cancer &
 Leukemia

Leukemia Cancer News - Return to Menu

Callisto's CEO Dr. Gary Jacob Discusses Launch of Human Clinical Trial of Cancer Drug to Treat Relapsed Leukemia in Interview

CEO Outlines Medical Promise and Market for New Drug Treatment for Acute Lymphocytic Leukemia on BiomedDiscoveries.com

LOS ANGELES--(BUSINESS WIRE)--Dec 6, 2005 - BiomedDiscoveries.com, http://www.BiomedDiscoveries.com, the online source for exclusive investor information in the biotechnology sector, announced today a newly available interview with Dr. Gary S. Jacob, CEO and CSO of Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4). In the interview, Dr. Jacob provides fresh insight and discussion about the start of the recently launched clinical trial of the Company's drug candidate L-Annamycin, which the Company is developing as a treatment for patients with relapsed or refractory acute lymphocytic leukemia (ALL).

In the interview, Dr. Jacob explains the newly launched adult clinical trials of L-Annamycin at The University of Texas M. D. Anderson Cancer Center in Houston, Texas, widely considered one the world's leading health care institutions for cancer treatment and research. The first patient with refractory or relapsed ALL entered the Phase I/II trial on December 1, 2005, under the direction of principal investigator Dr. Hagop Kantarjian, Chairman of the Department of Leukemia, and a leader in the field of leukemia.

Dr. Jacob said L-Annamycin has shown promise as a potential life-saving treatment alternative for some of the most desperately ill leukemia patients.

L-Annamycin is a member of an already proven class of anti-cancer drugs, but presents a novel therapeutic profile, including indications of effectiveness on multi-drug-resistant tumors. This feature is what may enable L-Annamycin to be used as a treatment for so-called relapsed patients, or patients who have stopped responding positively to all available drug treatments, and have few or no options for further treatment. The drug has also demonstrated indications of a substantially reduced cardiotoxic effect, or toxicity to the heart, compared with other common anti-cancer drugs.

In previous studies, L-Annamycin has demonstrated encouraging therapeutic results in preclinical and human clinical trials as a potentially viable treatment for not only ALL but for another form of leukemia, acute myelogenous leukemia (AML). This devastating and usually terminal blood and bone marrow disease is the more common type of leukemia in adults, with more than 10,000 new cases diagnosed annually. L-Annamycin is being developed as a treatment for both ALL and AML.

This online streaming audio interview is available free of charge to interested investors by visiting http://www.BiomedDiscoveries.com.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company committed to the development of innovative new drugs to treat cancer and other major diseases and health threats. Currently, the Company's drug development pipeline includes anti-cancer drugs to treat blood, or hematological, cancers, and related diseases, as well as new drugs with Homeland Security applications designed to protect against potential bio-warfare agents, including staphylococcus and streptococcus. Currently, Callisto is developing two anti-cancer drug candidates to treat multiple myeloma and leukemia, both serious blood cancers. The Company's L-Annamycin drug candidate entered a clinical trial to treat adult relapsed or refractory acute lymphocytic leukemia (ALL) on December 1, 2005. L-Annamycin has a novel therapeutic profile that includes the potential to treat patients whose cancers have shown resistance to other cancer drugs; it also has shown potential for significantly reduced cardiotoxicity, or danger to the heart, compared with existing anthracycline cancer drugs. Callisto's anti-cancer drug Atiprimod is being explored as a treatment for relapsed or refractory multiple myeloma. Atiprimod is currently in a Phase I/IIa clinical trial in relapsed or refractory multiple myeloma patients at four clinical sites in the United States.

Callisto also has another exciting program based on its proprietary technology on guanylate cyclase receptor agonist (GCRA). U.S. Patent and Trademark Office has given a Notice of Allowance on a patent for a novel drug compound created by Callisto scientists to treat a variety of inflammatory diseases of the bowel, including colon cancer. The drug is first-in-class of a new category of compounds with the potential to revolutionize therapy for gastro-intestinal disease, while presenting virtually no known side effects or toxicity. The preclinical efficacy of the lead GCRA peptide SP304 has been demonstrated in animal models for ulcerative colitis. Callisto plans to advance the lead drug candidate for clinical evaluation in humans in 2006. Callisto also has received a major biodefense partnership grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a monoclonal antibody and vaccine against bacterial superantigen toxins. Bacterial superantigens are among the most lethal of toxins that can potentially be used as bioweapons. For investor-specific information about Callisto, including recent news and stock price data, please visit http://www.trilogy-capital.com/tcp/callisto/. For an Investor Fact Sheet about Callisto, please visit http://www.trilogy-capital.com/tcp/callisto/factsheet.html. To view an informational presentation of the Company's development pipeline of drug candidates, visit http://www.trilogy-capital.com/tcp/callisto/powerpoint.html. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. For additional information, please visit www.callistopharma.com.

About BiomedDiscoveries.com

BiomedDiscoveries.com provides exclusive commentary, research, interviews and other information about the smallcap investment marketplace. BiomedDiscoveries.com strives to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on BiomedDiscoveries.com include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. It is located at http://www.BiomedDiscoveries.com.

Forward-Looking Statements

Statements made on BiomedDiscoveries.com may contain forward-looking statements made by senior management of the companies presented here that involve risks and uncertainties, such as statements about plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and performances, or achievements expressed or implied by the forward-looking statements. Actual future results and trends may differ materially from those made in -- or suggested by -- statements presented here due to a variety of factors. Consequently, you should not place undue reliance on any forward-looking statements made here. Many of these and other risks and uncertainties are discussed in greater detail in recent filings with the Securities Exchange Commission for the companies that are presented by BiomedDiscoveries.com.

Compensation and Other Disclosures

BiomedDiscoveries.com is a wholly owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations services to public companies. The companies presented by BiomedDiscoveries.com are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Callisto pays $12,500 per month through July 2006 and thereafter for so long as Trilogy is retained to provide investor relations services. In connection with its engagement, Trilogy received non-transferable warrants from this company to purchase 1,793,322 shares of common stock for $1.03 per share expiring in July 2008, provided that the warrants are not exercisable to the extent that following exercise Trilogy would beneficially own 5% or more of the outstanding common stock of the company.

Contact BiomedDiscoveries.com Astra Thomas, 800-592-6061

Site Map | Acute Myelogenous Leukemia